RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating)'s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.51 and traded as low as $0.94. RedHill Biopharma shares last traded at $1.02, with a volume of 1,519,624 shares traded.
RedHill Biopharma Price Performance
The company's 50 day moving average is $0.91 and its 200 day moving average is $1.51. The company has a current ratio of 0.98, a quick ratio of 0.79 and a debt-to-equity ratio of 9.42. The stock has a market capitalization of $53.74 million, a price-to-earnings ratio of -0.54 and a beta of 1.86.
Get
RedHill Biopharma alerts:
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last announced its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The firm had revenue of $18.24 million for the quarter. During the same quarter in the prior year, the business earned ($0.53) earnings per share. Research analysts anticipate that RedHill Biopharma Ltd. will post -0.95 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of RDHL. HighTower Advisors LLC acquired a new position in RedHill Biopharma in the fourth quarter valued at $32,000. Virtu Financial LLC increased its stake in RedHill Biopharma by 59.8% in the second quarter. Virtu Financial LLC now owns 42,940 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 16,076 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new position in RedHill Biopharma in the fourth quarter valued at $71,000. Millennium Management LLC acquired a new position in RedHill Biopharma in the second quarter valued at $324,000. Finally, GSA Capital Partners LLP increased its stake in RedHill Biopharma by 108.4% in the fourth quarter. GSA Capital Partners LLP now owns 218,338 shares of the biotechnology company's stock valued at $563,000 after purchasing an additional 113,584 shares during the period. 11.08% of the stock is currently owned by institutional investors and hedge funds.
About RedHill Biopharma
(Get Rating)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Recommended Stories
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- PENN Entertainment Stock is Reset and Ready to Rebound
- 3 Payroll Software Makers Set For Growth In 2023
- NYSE Stocks Give Investors a Variety of Quality Options
- Zoom Video Communications Valuation Is Realigned With Reality
- The J.M. Smucker Company Proves Why Staples Are Outperforming
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
